Chemotherapy for Bronchogenic Carcinoma
- 30 May 1977
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 237 (22), 2392-2396
- https://doi.org/10.1001/jama.1977.03270490032019
Abstract
A combination chemotherapy (MACC) consisting of methotrexate, doxorubicin hydrochloride (Adriamycin), cyclophosphamide, and lomustine (CCNU) was given to 41 patients with stage III bronchogenic carcinoma, 34 of whom had disseminated disease. The objective response rate was 46% for all patients with a median actuarial survival of nine months. Response was seen in all cell types, including four of ten patients with squamous cell carcinoma, six of 17 with adenocarcinoma, and six of seven with small-cell anaplastic carcinoma. Prolongation of survival was apparent for patients of all cell types. Toxic reactions were moderate and allowed for easy outpatient use. (JAMA 237:2392-2396, 1977)This publication has 8 references indexed in Scilit:
- The Staging of Lung CancerPublished by Springer Nature ,2012
- Bacon (bleomycin, adriamycin, CCNU, oncovin and nitrogen mustard) in squamous lung cancer. Experience in fifty patientsCancer, 1976
- Clinical comparison of the nitrosoureasCancer, 1975
- Trends in Survival Rates of Patients with CancerNew England Journal of Medicine, 1975
- Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancerCancer, 1975
- Adriamycin in advanced bronchogenic carcinomaCancer, 1974
- AdriamycinAnnals of Internal Medicine, 1974
- Comparative toxicity on leukocytes and platelets of two regimens of CCNU: The relationship between maximum dose and optimum doseEuropean Journal of Cancer (1965), 1973